Screening for Neuroblastoma Using Urinary Catecholamines: The End of the Story
Open Access
- 5 May 2021
- journal article
- editorial
- Published by Oxford University Press (OUP) in JNCI Cancer Spectrum
- Vol. 5 (4) , pkab042
Abstract
Neuroblastoma (NB) is the most common extracranial solid tumor of childhood, with a peak incidence at birth. About 40% of children are diagnosed in the first year of life, and by 6 years of age, more than 90% of children will have presented with the disease. Unlike cancers in adults, where many common malignancies can be preclinically detected, including the 4 most prevalent cancers—lung, colon, prostate, and breast—no pediatric cancer was deemed easily detectable by screening. The 1 exception was NB because it has been known for decades that 90% of patients presenting clinically excrete elevated catecholamine metabolites in their urine. Furthermore, if children present with NB at a young age—specifically, under 18 months of age—the prognosis is outstanding, with about 90% of cases cured. Based on these facts, Sawada and Japanese colleagues pioneered NB screening programs in the 1970s ( 1), with early results suggesting that overall survival in the children screened improved. Unfortunately, survival can look artificially increased if screening programs diagnose patients whose tumors would have spontaneously regressed, a known phenomenon in NB. One must determine population-based mortality to determine true efficacy of any such intervention.Keywords
This publication has 11 references indexed in Scilit:
- Incidence of Neuroblastoma After a Screening ProgramJournal of Clinical Oncology, 2007
- Health and Economic Benefits of Well-Designed Evaluations: Some Lessons From Evaluating Neuroblastoma ScreeningJNCI: Journal of the National Cancer Institute, 2005
- A Halt to Neuroblastoma Screening in JapanNew England Journal of Medicine, 2004
- Screening of Infants and Mortality Due to NeuroblastomaNew England Journal of Medicine, 2002
- Neuroblastoma Screening at One Year of AgeNew England Journal of Medicine, 2002
- Biological aspects of neuroblastomas identified by mass screening in quebecMedical and Pediatric Oncology, 2001
- Randomized controlled trials in population-based intervention studies are not always feasibleMedical and Pediatric Oncology, 1999
- A population-based study of the usefulness of screening for neuroblastomaThe Lancet, 1996
- Screening for Neuroblastoma in Infants: Investigate or Implement?Pediatrics, 1990
- MASS SCREENING FOR NEUROBLASTOMA IN INFANTS IN JAPANThe Lancet, 1984